best stock buys

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-101880049&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/101880049/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; FABRICE COFFRINI/AFP/Getty Images

Companies keep churning out impressive earnings, but the market doesn&a;rsquo;t seem to give them much credit. Instead, fear and caution remain the watchwords as the Dow Jones Industrial Average enters Wednesday on a five-session losing streak.

&l;strong&g;Morning Earnings Wrap&l;/strong&g;

Boeing became the latest member of the D&l;span&g;ow Jones Industrial Average&a;nbsp;&l;/span&g;30 to smash Wall Street analysts&a;rsquo; projections early Wednesday, firing up earnings per share of $3.64 vs. analysts&a;rsquo; consensus of $2.56. Revenue of $23.38 billion was more than $1 billion ahead of the $22.2 billion analysts had expected, and the company also raised its outlook. Strength in the commercial air division helped Boeing project a healthy sales picture.

best stock buys: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap hair loss stocks Aclaris Therapeutics (NASDAQ: ACRS), Cytori Therapeutics (NASDAQ: CYTX) and RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) are trying to tap into a big market as currently, there are only two FDA-approved drugs available for the treatment of Androgenetic Alopecia (AGA) -also known as male or female pattern baldness (one of which cannot be used by women). Thus, a significant unmet need exists for a safe andefficacious product especially since its experienced by 70% of men and 40% of women as they age.

  • [By Logan Wallace]

    Aclaris Therapeutics (NASDAQ:ACRS) has received a consensus recommendation of “Hold” from the eight research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $46.00.

  • [By Chris Lange]

    Aclaris Therapeutics Inc. (NASDAQ: ACRS) saw its shares make a handy gain on Friday after the company announced the pricing of its secondary offering. The company intends to price its 4 million shares at $22.75 per share, with an overallotment option for an additional 600,000 shares. At this price the entire offering is valued up to $104.65 million.

best stock buys: Primerica, Inc.(PRI)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Companies Reporting After The Bell
    Marriott International, Inc. (NASDAQ: MAR) is projected to post quarterly earnings at $1.22 per share on revenue of $5.72 billion.
    Electronic Arts Inc. (NASDAQ: EA) is estimated to post quarterly earnings at $1.04 per share on revenue of $5.68 billion.
    The Walt Disney Company (NYSE: DIS) is projected to post quarterly earnings at $1.68 per share on revenue of $14.05 billion.
    Papa John's International, Inc. (NASDAQ: PZZA) is expected to post quarterly earnings at $0.62 per share on revenue of $441.73 million.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is projected to post quarterly earnings at $2.77 per share on revenue of $434.87 million.
    Sun Life Financial Inc. (NYSE: SLF) is estimated to post quarterly earnings at $0.89 per share on revenue of $6.38 billion.
    LATAM Airlines Group S.A. (NYSE: LTM) is expected to post quarterly earnings at $0.16 per share on revenue of $2.70 billion.
    Liberty Global plc (NASDAQ: LBTYA) is projected to post quarterly earnings at $0.02 per share on revenue of $4.05 billion.
    TripAdvisor, Inc. (NASDAQ: TRIP) is expected to post quarterly earnings at $0.16 per share on revenue of $362.11 million.
    The Wendy's Company (NASDAQ: WEN) is projected to post quarterly earnings at $0.1 per share on revenue of $379.98 million.
    A-Mark Precious Metals, Inc. (NASDAQ: AMRK) is expected to post quarterly earnings at $0.06 per share on revenue of $1.69 billion.
    Monster Beverage Corporation (NASDAQ: MNST) is estimated to post quarterly earnings at $0.4 per share on revenue of $849.38 million.
    Convergys Corporation (NYSE: CVG) is expected to post quarterly earnings at $0.4 per share on revenue of $670.10 million.
    ScanSource, Inc. (NASDAQ: SCSC) is projected to post quarterly earnings at $0.7 per share on revenue of $875.91 million.
    KAR Auction Services, Inc. (NYSE: KAR) is expected to post quarterly earnings at $0.76 per share on revenue of $923.13

  • [By Joseph Griffin]

    Primerica (NYSE:PRI) has been assigned a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating. The average 1-year target price among brokers that have issued a report on the stock in the last year is $103.00.

best stock buys: RELM Wireless Corporation(RWC)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested shorting small cap wireless communications manufacturer RELM Wireless Corporation (NYSEMKT: RWC):

best stock buys: Intercept Pharmaceuticals, Inc.(ICPT)

Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Peter Graham]

    Small cap liver biopharmaceutical stock Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reportedQ2 2017 earnings before the market opened on Monday with both the top and bottom lines beating expectations plus the Companyreported that amid-stage clinical trial met its primary endpoint; but sharesended the day down13.26%. Intercept Pharmaceuticals recognized $30.4 million of net sales of Ocaliva for Q2 2017 versus $75k and a net loss of $86.6 million versus a net loss of $77.3 million. Ocaliva was approved by the U.S.FDA in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. As of June 30, 2017,the Companyhad cash, cash equivalents and investment securities available for sale of approximately $550.3 million versus$689.4 million as of December 31, 2016. The CEO commented:

  • [By Paul Ausick]

    Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) dropped more than 17% Friday to post a new 52-week low of $60.97 after closing Thursday at $73.70. The 52-week high is $172.75. Volume of more than 10 million shares traded was about 12 times the daily average. The FDA on Thursday issued a warning letter on the company’s liver disease treatment.

best stock buys: DXP Enterprises Inc.(DXPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of DXP Enterprises Inc (NASDAQ: DXPE) got a boost, shooting up 22 percent to $40.27 after the company posted upbeat quarterly results.

    Nature's Sunshine Prod. (NASDAQ: NATR) shares were also up, gaining 28 percent to $11.35 as the company disclosed that it has received its direct selling license in China.

  • [By Lisa Levin]

    Shares of DXP Enterprises Inc (NASDAQ: DXPE) were down 17 percent to $24.00. DXP Enterprises reported preliminary revenue of $228 million to $231 million for the third quarter.

best stock buys: Advanced Semiconductor Engineering, Inc.(ASX)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, technology shares rose by just 0.2 percent. Meanwhile, top losers in the sector included Advanced Semiconductor Engnrng Inc (ADR) (NYSE: ASX), down 6 percent, and Bitauto Hldg Ltd (ADR) (NYSE: BITA) down 6 percent.

  • [By Lisa Levin]

    In trading on Tuesday, technology shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Advanced Semiconductor Engnrng Inc (ADR) (NYSE: ASX), down 6 percent, and QAD Inc. (NASDAQ: QADB) down 5 percent.

  • [By WWW.THESTREET.COM]

    Cramer was bearish on Prudential (PRU) , Advanced Semiconductor Engineering (ASX) and ZTO Express (ZTO) .

    Read more of Cramer’s comments about the stocks in the Lightning Round.

  • [By Peter Graham]

    A look at the long term performance of small cap Amkor Technology along with Taiwan based peers like large cap mid cap Siliconware Precision Industries (NASDAQ: SPIL) and Advanced Semiconductor Engineering (NYSE: ASX) show considerable volatility:

Leave a Reply

Your email address will not be published. Required fields are marked *